Table 2.
In vivo studies of anticancer peptides and proposed mode of action.
| Peptidea | Mode of action | Type of tumor |
|---|---|---|
| α-Helical | ||
| Magainin and analogues | Lytic | Murine ascites tumors (Baker et al., 1993); melanoma xenograft in nude mice (Soballe et al., 1995) |
| Melittin/avidin-conjugate | Lytic | Melanoma in mice (Holle et al., 2003) |
| Polybia-MPI/MPI-1 | Necrosis | Sarcoma xenograft tumors in mice (Zhang et al., 2010) |
| β-sheet | ||
| Human α-defensins | Apoptosis | Human lung adenocarcinoma xenograft in nude mice (Xu et al., 2008) |
| Gomesin | Necrosis | Murine melanoma (Rodrigues et al., 2008) |
| Lactoferricin B | Necrosis/Apoptosis | Fibrosarcoma, melanoma, colon carcinoma (Eliassen et al., 2002); Xenografting of SH-SY-5Y cells in nude rats (Eliassen et al., 2006); inhibition of metastasis of melanoma and lymphoma in mice (Yoo et al., 1997) |
| RGD-tachyplesin | Apoptosis | Melanoma mice (Chen et al., 2001) |
| Others | ||
| Dolastatin 10 | Anti-proliferative | Indolent lymphoma, Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (Simmons et al., 2005) |
| Synthetic | ||
| [d]-K6L9 | Necrosis | Breast cancer in SCID/NCr mice (Papo et al., 2006) |
| [d]-H6L9 | Lytic | 22RV1 prostate cancer in mice (Makovitzki et al., 2009) |
a
Source and amino acid composition of peptides are listed in Table 1.